IMS Health (IMS) Approves $250M Common Stock Buyback Plan

IMS Health Holdings, Inc. (NYSE: IMS) announced that its board of directors approved a stock repurchase program authorizing the repurchase of up to $250 million of its common stock.

The share repurchase program does not obligate the company to repurchase any particular amount of common stock, and it could be modified, suspended or discontinued at any time. The timing and amount of repurchases are determined by IMS Health’s management at its discretion based on a variety of factors such as the market price of its common stock, corporate requirements, general market and economic conditions, legal requirements and compliance with the terms of the company’s senior secured credit facilities and the indentures governing its outstanding senior notes. Purchases of the company’s common stock may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, in privately negotiated transactions or by other means in accordance with federal securities laws. The share repurchase program does not have a specified expiration date.

You May Also Be Interested In

• Havas repurchases 3,000 shares under €50M buyback program
• ANI Pharmaceuticals to appeal Delaware court rulings in CG Oncology case
• Hilton Grand Vacations refinances $850M term loan, extends to 2033